xprot GmbH was founded in 2021 and is based in Mainz, Germany.

xprot is dedicated to developing new therapeutic approaches for lung cancer. The company has identified a protein that is downregulated in tumor samples from patients. Upregulation of the gene in cancer cells led to a halt in growth. The company's goal is to restore the expression of the gene in tumor cells to stop uncontrolled tumor growth and stimulate the immune response. Additionally, the gene serves as a biomarker for selecting suitable patients.